Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.62 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.62 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.60 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | RXRA | P19793 | 1/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.56 |
| ▸ | TTR | P02766 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2708209 | 0.91 | SRD5A2 (0.71) | KDM4EPOLBSRD5A2AKR1C3RXRA | |
| Hydrochloric Acid SCHEMBL2710360 | 0.89 | SRD5A2 (0.69) | KDM4EPOLBSRD5A2AKR1C3RXRA | |
| Hydrochloric Acid SCHEMBL2710358 | 0.89 | SRD5A2 (0.69) | KDM4EPOLBSRD5A2AKR1C3RXRA | |
| SCHEMBL9702751 | 0.88 | KDM4E (0.77) | CA1CA2KDM4EPOLBLPAR1 | |
| SCHEMBL16378706 | 0.88 | MTNR1B (0.62) | PGRKDM4EPOLBSRD5A2MTNR1B | |
| SCHEMBL2867923 | 0.88 | AKR1C3 (0.73) | PGRKDM4EPOLBAKR1C3SMN1; SMN2 | |
| SCHEMBL28600429 | 0.87 | CA1 (0.70) | CA1CA2KDM4EPOLBSRD5A2 | |
| SCHEMBL2857877 | 0.86 | AKR1C3 (0.77) | CA1CA2PGRKDM4EPOLB | |
| SCHEMBL16429487 | 0.86 | AKR1C3 (0.82) | KDM4EPOLBSRD5A2AKR1C3 | |
| SCHEMBL2511835 | 0.85 | CA1 (0.87) | CA1CA2KDM4EPOLBSRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773352-B1 | 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS | RES TRIANGLE INST (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9512105-B2 | 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150005315-A1 | 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2015-01-01 | — | — | US | disclosed |
| EP-2773352-A2 | 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS | Research Triangle Institute, International (US) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013086496-A2 | 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20110106241-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2011-05-05 | — | — | US | disclosed |
| US-20110106241-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2011-05-05 | — | — | US | disclosed |
| WO-2009146112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20060235035-A1 | Novel methoxybenzamibe compounds for use in mch receptor related disorders | 7TM PHARMA A/S (DK) | 2006-10-19 | — | — | US | disclosed |
| EP-1497260-A1 | NOVEL METHOXYBENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM Pharma A/S (DK) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087045-A1 | NOVEL METHOXYBENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM PHARMA A/S (DK) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110106241-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE | SPHK2, SPHK1, S1PR2 | CA1 3622/4885CA2 1665/4885PGR 3869/4885 |
| US-20150005315-A1 | 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS | OPRK1, OPRM1, OPRD1 | CA1 4184/4885CA2 3930/4885PGR 163/4885 |
| US-20060235035-A1 | Novel methoxybenzamibe compounds for use in mch receptor related disorders | GPR119, MCHR2, HCRTR2 | CA1 4551/4885CA2 2139/4885PGR 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.